Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Capital Expenditures: 2012-2025

Historic Capital Expenditures for Ptc Therapeutics (PTCT) over the last 13 years, with Sep 2025 value amounting to $3.4 million.

  • Ptc Therapeutics' Capital Expenditures rose 559.96% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.3 million, marking a year-over-year increase of 23.52%. This contributed to the annual value of $6.5 million for FY2024, which is 77.14% down from last year.
  • Latest data reveals that Ptc Therapeutics reported Capital Expenditures of $3.4 million as of Q3 2025, which was up 161.58% from $1.3 million recorded in Q2 2025.
  • Ptc Therapeutics' Capital Expenditures' 5-year high stood at $10.3 million during Q1 2023, with a 5-year trough of -$7.4 million in Q2 2024.
  • Moreover, its 3-year median value for Capital Expenditures was $3.8 million (2024), whereas its average is $3.8 million.
  • Per our database at Business Quant, Ptc Therapeutics' Capital Expenditures slumped by 218.09% in 2024 and then soared by 559.96% in 2025.
  • Over the past 5 years, Ptc Therapeutics' Capital Expenditures (Quarterly) stood at $8.7 million in 2021, then dropped by 1.19% to $8.6 million in 2022, then plummeted by 35.44% to $5.6 million in 2023, then tumbled by 32.32% to $3.8 million in 2024, then skyrocketed by 559.96% to $3.4 million in 2025.
  • Its Capital Expenditures was $3.4 million in Q3 2025, compared to $1.3 million in Q2 2025 and $1.7 million in Q1 2025.